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INTRODUCTION: Eighty to ninety percent 
of APAP is metabolized by glucuronidation 
and sulfation and excreted in urine. The 
remaining 5-10% of APAP is metabolized by 
CYP450/CYP2E into N-acetyl-p-
benzoquinone imine (NAPQI), the toxic 
metabolite responsible for APAP 
hepatotoxicity.3 NAPQI is inactivated when 
conjugated to tripeptide glutathione. During 
APAP overdose, excessive quantities of 
NAPQI and depleted glutathione stores lead 
to hepatotoxicity.3 There exists only two case 
reports on hepatotoxicity associated with 
therapeutic doses of IV APAP in post-
operative patients with native livers, 
however, one was confounded by post-
operative shock liver.4,5 There is no validated 
nomogram to guide treatment of IV APAP 
overdose or toxicity. NAC therapy remains 
the mainstay for PO APAP overdose. 
 
CASE REPORT: A 69 year old male with a 
past medical history of secondary biliary 
liver cirrhosis status post orthotopic liver 
transplantation in 2006, Hepatocellular 
carcinoma of the explanted liver, splenic 
artery aneurysm status post splenectomy and 
newly diagnosed prostate adenocarcinoma 
was admitted to the Urology service for 
planned robotic-assisted prostatectomy. 
Eighteen days prior to presentation, the 
patient was medically cleared by Transplant 
Hepatology for prostatectomy. He was noted 
to have a normal functioning hepatic graft 
and advised to continue taking tacrolimus 0.5 
mg twice daily. At that time, 
aminotransferase (AST) was 23 IU/L, alanine 
aminotransferase (ALT) 24 IU/L, total 
bilirubin (TBili) 1.4 mg/dL, and international 
normalized ratio (INR) 1.0. 
He underwent uncomplicated robotic-
assisted prostatectomy, requiring no fluid 
resuscitation, vasopressor support or blood 
products. Post-operatively, vital signs 
remained normal with no episodes of 
hypotension. Physical exam was notable for 
mild tenderness to palpation around the 
laparoscopic incision sites. He was started on 
a clear liquid diet and IV APAP 1000 mg 
every 6 hours for 36 hours, followed by PO 
APAP 650 mg every 6 hours for post-
operative pain. 
On post-operative day 1, AST was 2275 
IU/L, ALT 2521 IU/L, TBili 1.3 mg/dL, and 
INR 1.4. On post-operative day 2, AST was 
2751 IU/L, ALT 3447 IU/L, TBili 1.9 mg/dL 
and INR 1.5 (Figure 1).  
Figure 1. AST, ALT, Total Bilirubin Levels 
Before, During, and After Hospital 
Admission 
 
The patient developed a diffuse, pruritic 
maculopapular rash around his torso and 
bilateral upper arms, unrelieved by oral 
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diphenhydramine. All orders for 
acetaminophen were stopped. Liver Doppler 
ultrasound was normal. By this time, the 
patient had received 5000 mg of IV APAP 
and 650 mg of PO APAP total. A serum 
acetaminophen level was drawn 10 hours 
after the last IV APAP dose and noted to be 
< 15 ug/mL. Hepatology was consulted. 
The patient reported consuming daily herbal 
supplements for the past 14 months, 
including saw palmetto, pygeum, cranberry 
extract, pumpkin seed extract and beta-
sitosterol. He stopped taking the herbal 
supplements 7 days prior to the 
prostatectomy. He denied alcohol use and 
reported minimal nausea, but no vomiting. 
His average daily intake was 3.5 liters. Work 
up for infectious etiologies was negative. 
The patient was started on IV NAC, with a 
loading dose of 150 mg/kg followed by a 
maintenance dose of 50 mg/kg over 4 hours, 
then 100 mg/kg over 16 hours. Within 18 
hours, AST was 1350 IU/L, ALT 2836 IU/L, 
and INR 1.5. TBili increased to 2.4 mg/dL. 
Following completion of IV NAC therapy, 
AST was 986 IU/L, ALT 2340 IU/L, TBili 
1.9 mg/dL, and INR 1.4. His macular papular 
rash resolved during IV NAC therapy. 
The patient was discharged home on post-
operative day 4. Labs during his outpatient 
Hepatology follow-up appointment 4 days 
after discharge were AST 62 IU/L, ALT 426 
IU/L, TBili 1.3 mg/dL, and INR 1.1. 
 
DISCUSSION: This is the first case of acute 
liver toxicity in a post-OLT patient who 
received therapeutic doses of IV APAP 
subsequently responded to IV NAC therapy. 
The patient's AST, ALT, TBili and INR were 
normal prior to IV APAP exposure. 
Elevations in AST, ALT, TBili, and INR 
improved after IV APAP was discontinued 
and IV NAC initiated. A serum APAP level 
drawn 10 hours after the last IV APAP 
administration was < 15 ug/mL, consistent 
with therapeutic dosage. There was no 
evidence of hypotension or APAP overdose 
in the electronic medical records. All other 
etiologies for acute liver toxicity were ruled 
out, including shock liver, infection and 
vascular compromise. 
Risk factors that have been shown to increase 
the risk of hepatotoxicity in APAP overdose 
patients include malnutrition, eating 
disorders, AIDS, alcoholism, antiepileptic 
medications, and tuberculosis medications.6 
Our patient did not have any of these risk 
factors. Although he experienced nausea 
post-operatively, daily total intake was 
adequate and there were no periods of fasting 
or malnutrition. It is unlikely the patient's 
hepatotoxicity was due to herbal drug 
induced liver injury or herbal-drug 
interactions with IV APAP. Case reports 
exist on saw palmetto associated cholestatic 
hepatotoxicity.7 However, prospective trials 
have found little evidence of liver injury 
linked to saw palmetto.8 There was no 
history of hepatotoxicity during the 14 
months that the patient consumed saw 
palmetto and he ceased saw palmetto 
consumption 7 days prior to admission. 
Online Pubmed literature searches on 
hepatotoxicity due to pygeum, cranberry 
extract, pumpkin seed extract or beta-
sitosterol did not yield results. 
The patient's transplant liver may have been 
predisposed to IV APAP toxicity, even at 
therapeutic doses. It is possible APAP 
metabolism is altered in transplant livers 
compared to native livers. A study on 13 liver 
transplant patients concluded APAP 
metabolism was transiently altered in 
orthotopic livers following liver 
transplantation, resulting in enhanced 
NAPQI production.9 Liver Transplant 
Centers in the Scientific Registry of 
Transplant Recipients have issued post-OLT 
guidebooks for patients, recommending no 
more than 1500 mg to 2000 mg of PO APAP 
daily, lower than the daily maximum limit of 
4000 mg.10,11,12 Furthermore, studies show 
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decreased glutathione levels in transplant 
livers after undergoing pre-transplant cold 
storage preservation and post-transplant 
reperfusion. It is possible transplant livers 
carry less glutathione stores, rendering them 
more susceptible to hepatotoxicity from 
NAPQI concentrations that a native liver 
would tolerate.13 Further studies on what is 
considered safe, therapeutic IV APAP dosing 
in post-OLT patients is needed to prevent 
hepatotoxicity in this patient population. 
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